HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

XUANZHUBIO-B

8.880

-0.685-7.16%

Volume:1.37M

Turnover:12.42M

Market Cap:4.60B

PE:-14.35

High:9.555

Open:9.500

Low:8.765

Close:9.565

52wk High:96.900

52wk Low:8.765

Shares:518.00M

HK Float Shares:517.95M

Volume Ratio:0.30

T/O Rate:0.26%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.619

ROE:-19.61%

ROA:-9.68%

PB:3.04

PE(LYR):-14.35

PS:38.12

Loading ...

Overview Company News Filings

Xuanzhu Biopharmaceutical Enrolls First Patient in Anaprazole Sodium Study

MT Newswires Live

Four Hong Kong-listed Companies Launch IPO Processes, Including Medical Robotics Firm, While Able Digital Inks Major Partnership with Alibaba Cloud

Xuanzhu Bio-B Initiates Phase III Trial for H. Pylori Eradication with New Anaprazole Sodium Indication

Xuanzhu Biopharma enrolls first patient in Phase III trial of anaprazole sodium for H. pylori eradication

XUANZHUBIO-B Announces Election of Employee Representative Director

Xuanzhu Biopharmaceutical Tightens Governance Framework in Revised Articles; Confirms 9-Member Board and HK$517.95 Million Share Capital

Bulletin Express

Xuanzhu Biopharmaceutical files director list with Hong Kong Stock Exchange

Xuanzhu Biopharma names Yue Xin employee representative director after election

Xuanzhu Bio Converts 357.25 Million Unlisted Shares to H Shares, Expanding Total Issued Capital to 517.95 Million

Bulletin Express

XUANZHUBIO-B Shares Surge as Three Key Products Advance to Commercial Stage

Xuanzhu Biopharma to Seek Shareholder Nod on 2025 Reports, Profit Distribution and Board Mandates at 18 June 2026 AGM

Bulletin Express

Xuanzhu Biopharmaceutical announces annual general meeting

Xuanzhu Biopharmaceutical seeks bylaw changes to scrap supervisory committee, shift oversight to audit committee

Registration Open for "Zhihui Financial 2026 Summer Roadshow Conference"

Xuanzhu Biopharma Converts 357.25 Million Unlisted Shares into H Shares, Lifting Issued Share Base by 68.97%

Bulletin Express

Xuanzhu Biopharmaceutical Completes H-Share Full Circulation, Converts 357.25 Million Unlisted Shares

Bulletin Express

XUANZHUBIO-B Completes Full Circulation of H Shares

Xuanzhu Biopharmaceutical converts 357,245,794 unlisted shares into H shares

Here's Why We're Not Too Worried About Xuanzhu Biopharmaceutical's (HKG:2575) Cash Burn Situation

Simply Wall St.

XUANZHUBIO-B Accelerates Domestic Commercialization and Secures Major Overseas Licensing Deal, Broadening Growth Prospects

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/02575/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02575","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"XUANZHUBIO-B","latestPrice":8.88,"timestamp":1789027724004,"preClose":9.565,"halted":0,"volume":1365500,"delay":0,"changeRate":-0.07161526398327221,"floatShares":517947790,"shares":518000000,"eps":-0.6189415159737144,"marketStatus":"Not Yet Opened","change":-0.685,"latestTime":"09-10 16:08:44","open":9.5,"high":9.555,"low":8.765,"amount":12420785,"amplitude":0.082593,"askPrice":8.88,"askSize":6500,"bidPrice":8.865,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.4918307814337918,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":0,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":9.565,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":0.3009555023089365,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","floatShares":517947790,"roa":"-9.68%","roe":"-19.61%","lyrEps":-0.618942,"volumeRatio":0.3009555023089365,"shares":518000000,"dividePrice":0,"high":9.555,"amplitude":0.082593,"preClose":9.565,"low":8.765,"week52Low":8.765,"pbRate":"3.04","psRate":"38.12","week52High":96.9,"institutionHeld":0,"latestPrice":8.88,"committee":-0.733333,"eps":-0.6189415159737144,"divideRate":0,"volume":1365500,"delay":0,"ttmEps":-0.4918307814337918,"open":9.5,"prevYearClose":70.5,"prevWeekClose":10.43,"prevMonthClose":10.08,"prevQuarterClose":13.33,"fiveDayClose":11.12,"twentyDayClose":12.39,"sixtyDayClose":16.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02575\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02575","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"date":"2026-03-30","symbol":"02575","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02575\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02575\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02575\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02575","date":"2026-09-09","current":-18.054121,"percent":0.963636,"low":-70.039607,"twenty":-55.062726,"median":-42.005079,"eighty":-24.075629,"high":-18.714723,"avg":-41.045751,"sd":14.501145,"marketCap":4954170611},"quantilePoints":[{"date":"2025-10-17","current":-28.93414,"twenty":-27.261252,"median":-24.751919,"eighty":-23.367582,"marketCap":17558430081},{"date":"2025-10-24","current":-50.850969,"twenty":-50.816841,"median":-33.923646,"eighty":-26.424807,"marketCap":30869688284},{"date":"2025-10-31","current":-54.182971,"twenty":-53.663557,"median":-50.808309,"eighty":-28.95487,"marketCap":32941479444},{"date":"2025-11-07","current":-55.367666,"twenty":-55.639174,"median":-53.630543,"eighty":-30.992132,"marketCap":33640708960},{"date":"2025-11-14","current":-54.36116,"twenty":-55.639174,"median":-54.1994,"eighty":-41.200731,"marketCap":33122761170},{"date":"2025-11-21","current":-53.748657,"twenty":-55.319259,"median":-54.136108,"eighty":-50.782713,"marketCap":32734300328},{"date":"2025-11-28","current":-53.384655,"twenty":-55.070724,"median":-54.15954,"eighty":-50.923112,"marketCap":32630710770},{"date":"2025-12-05","current":-54.773392,"twenty":-55.070724,"median":-54.21583,"eighty":-51.627953,"marketCap":33537119402},{"date":"2025-12-12","current":-70.039607,"twenty":-55.665823,"median":-54.261136,"eighty":-53.311356,"marketCap":42963769180},{"date":"2025-12-19","current":-60.019152,"twenty":-56.570931,"median":-54.488669,"eighty":-53.433833,"marketCap":36903780037},{"date":"2025-12-24","current":-59.160975,"twenty":-59.157371,"median":-54.549256,"eighty":-53.581365,"marketCap":36489421805},{"date":"2026-01-02","current":-54.537602,"twenty":-59.158272,"median":-54.690337,"eighty":-53.655303,"marketCap":33770195908},{"date":"2026-01-09","current":-52.983682,"twenty":-59.049917,"median":-54.49123,"eighty":-52.274882,"marketCap":32889684665},{"date":"2026-01-16","current":-58.758617,"twenty":-58.846722,"median":-54.572443,"eighty":-53.169291,"marketCap":36593011363},{"date":"2026-01-23","current":-52.071916,"twenty":-58.705513,"median":-54.4959,"eighty":-52.506318,"marketCap":32397634264},{"date":"2026-01-30","current":-53.326607,"twenty":-57.909955,"median":-54.48995,"eighty":-52.506318,"marketCap":33329940286},{"date":"2026-02-06","current":-57.283358,"twenty":-57.848985,"median":-54.4959,"eighty":-52.506318,"marketCap":35893781847},{"date":"2026-02-13","current":-51.942748,"twenty":-58.578655,"median":-54.516751,"eighty":-52.506318,"marketCap":32734300328},{"date":"2026-02-20","current":-51.153455,"twenty":-58.517685,"median":-54.493565,"eighty":-52.321662,"marketCap":32190455148},{"date":"2026-02-27","current":-53.732962,"twenty":-57.403185,"median":-54.403912,"eighty":-52.138331,"marketCap":34184554140},{"date":"2026-03-06","current":-41.037619,"twenty":-57.295346,"median":-54.261136,"eighty":-51.687579,"marketCap":25897389500},{"date":"2026-03-13","current":-40.849477,"twenty":-57.283358,"median":-54.21583,"eighty":-50.904735,"marketCap":25897389500},{"date":"2026-03-20","current":-35.26408,"twenty":-56.603099,"median":-54.112473,"eighty":-49.228933,"marketCap":22271754970},{"date":"2026-03-27","current":-28.858752,"twenty":-56.47148,"median":-53.935449,"eighty":-43.741043,"marketCap":18179967429},{"date":"2026-04-02","current":-57.594339,"twenty":-56.497804,"median":-53.833069,"eighty":-43.169536,"marketCap":16087458357},{"date":"2026-04-10","current":-59.545661,"twenty":-57.25627,"median":-53.970491,"eighty":-43.400861,"marketCap":16760790484},{"date":"2026-04-17","current":-61.727863,"twenty":-57.517877,"median":-54.136108,"eighty":-43.645588,"marketCap":17382327832},{"date":"2026-04-24","current":-45.649544,"twenty":-57.360049,"median":-54.047185,"eighty":-44.053945,"marketCap":12855464147},{"date":"2026-04-30","current":-39.643505,"twenty":-57.292948,"median":-53.884259,"eighty":-43.829171,"marketCap":11166954352},{"date":"2026-05-08","current":-39.029961,"twenty":-57.269814,"median":-53.732962,"eighty":-42.509315,"marketCap":11032287927},{"date":"2026-05-15","current":-34.724128,"twenty":-57.211578,"median":-53.651177,"eighty":-40.906347,"marketCap":9841008010},{"date":"2026-05-22","current":-32.788719,"twenty":-57.162996,"median":-53.511235,"eighty":-40.250137,"marketCap":9271265441},{"date":"2026-05-29","current":-29.882198,"twenty":-57.033621,"median":-53.326607,"eighty":-39.029961,"marketCap":8478805322},{"date":"2026-06-05","current":-31.916861,"twenty":-56.603099,"median":-53.185623,"eighty":-36.605471,"marketCap":9069265802},{"date":"2026-06-12","current":-29.603728,"twenty":-56.47148,"median":-52.629422,"eighty":-35.26408,"marketCap":8406292631},{"date":"2026-06-18","current":-30.479088,"twenty":-56.448102,"median":-52.321662,"eighty":-34.687576,"marketCap":8675625482},{"date":"2026-06-26","current":-23.369212,"twenty":-56.068362,"median":-52.035899,"eighty":-32.252252,"marketCap":6619372756},{"date":"2026-07-03","current":-26.037742,"twenty":-55.925853,"median":-51.815163,"eighty":-31.259875,"marketCap":7380756007},{"date":"2026-07-10","current":-23.563382,"twenty":-55.788956,"median":-51.211683,"eighty":-30.461424,"marketCap":6671167535},{"date":"2026-07-17","current":-22.969392,"twenty":-55.712025,"median":-50.877852,"eighty":-29.911789,"marketCap":6526142154},{"date":"2026-07-24","current":-21.396832,"twenty":-55.583366,"median":-50.208288,"eighty":-29.704477,"marketCap":6080707054},{"date":"2026-07-31","current":-19.991935,"twenty":-55.489987,"median":-48.334812,"eighty":-29.33959,"marketCap":5692246212},{"date":"2026-08-07","current":-22.658402,"twenty":-55.433258,"median":-45.681548,"eighty":-28.96324,"marketCap":6463988419},{"date":"2026-08-14","current":-22.412159,"twenty":-55.37071,"median":-44.835824,"eighty":-28.336789,"marketCap":6401834684},{"date":"2026-08-21","current":-20.01067,"twenty":-55.365612,"median":-44.352491,"eighty":-26.122142,"marketCap":5728502557},{"date":"2026-08-28","current":-22.359148,"twenty":-55.267771,"median":-43.581952,"eighty":-25.329792,"marketCap":5474708140},{"date":"2026-09-04","current":-22.054147,"twenty":-55.10047,"median":-42.591003,"eighty":-24.406781,"marketCap":5402195449},{"date":"2026-09-09","current":-20.192794,"twenty":-55.062726,"median":-42.005079,"eighty":-24.075629,"marketCap":4954170611}],"updateTime":1789070369859},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02575\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645604874","title":"Xuanzhu Biopharmaceutical Enrolls First Patient in Anaprazole Sodium Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2645604874","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645604874?lang=en_us&edition=fundamental","pubTime":"2026-06-22 11:47","pubTimestamp":1782100063,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical  enrolled the first patient in the phase 3 study of its stomach-acid drug anaprazole sodium, according to a Sunday filing with the Hong Kong bourse.The firm plans to study the drug as a treatment for Helicobacter pylori, a common bacterial infection linked to ulcers, gastritis, and gastric cancer.The study will enroll 556 adults, and if successful, will help expand the treatment's approval from its current indication of duodenal ulcer.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168313115","title":"Four Hong Kong-listed Companies Launch IPO Processes, Including Medical Robotics Firm, While Able Digital Inks Major Partnership with Alibaba Cloud","url":"https://stock-news.laohu8.com/highlight/detail?id=1168313115","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168313115?lang=en_us&edition=fundamental","pubTime":"2026-06-22 09:07","pubTimestamp":1782090474,"startTime":"0","endTime":"0","summary":"Several significant corporate developments have been announced in the Hong Kong market, covering new share offerings, strategic partnerships, and investment activities. Key Corporate Actions The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1207","BK1558","01250","BK1235","02697","LU1993786604.SGD","BK1228","SCGEY","BK1554","LU1023057109.AUD","02657","300750","BK1154","02687","03952","06936","LU1807302812.USD","BK1216","LU0880133367.SGD","LU1960683339.HKD","06887","BK1116","LU1152091754.HKD","03750","LU0359201612.USD","BK1151","LU1152091168.USD","06915","01798","002352","LU0067412154.USD","02558","02575","BK1610","LU0359201885.HKD","BK1560","LU0359202008.SGD","00697","BK1594","06715","BK1191","LU1008478684.HKD","LU2213484517.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122383034","title":"Xuanzhu Bio-B Initiates Phase III Trial for H. Pylori Eradication with New Anaprazole Sodium Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1122383034","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122383034?lang=en_us&edition=fundamental","pubTime":"2026-06-21 18:14","pubTimestamp":1782036871,"startTime":"0","endTime":"0","summary":"Xuanzhu Bio-B (02575) has announced that its self-developed innovative drug, Anaprazole Sodium Enteric-coated Tablets (brand name: Anjiuwei®), has successfully enrolled the first patient into a Phase...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575","BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645628097","title":"Xuanzhu Biopharma enrolls first patient in Phase III trial of anaprazole sodium for H. pylori eradication","url":"https://stock-news.laohu8.com/highlight/detail?id=2645628097","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645628097?lang=en_us&edition=fundamental","pubTime":"2026-06-21 18:05","pubTimestamp":1782036350,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical enrolled the first patient in a Phase III trial of anaprazole sodium in Helicobacter pylori eradication therapy.Trial results have not been presented; the study will assess whether the regimen can clear infection safely versus an esomeprazole-based comparator.The study targets 556 adults across multiple centers with a 14-day treatment course.Anaprazole sodium is already marketed in China for duodenal ulcer; success could broaden its label and support faster commercial uptake.The company cited China’s H. pylori drug market at RMB 5.5 billion in 2024, projecting RMB 6.8 billion in 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to genera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260621:nNDL8bPT69:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","00460","BK1600","BK1515","BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188910815","title":"XUANZHUBIO-B Announces Election of Employee Representative Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1188910815","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188910815?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:28","pubTimestamp":1781778509,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) has issued a formal announcement regarding a board appointment.The company's employee representative congress convened on June 18, 2026.During the meeting, Ms. Yue Xin was...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153865036","title":"Xuanzhu Biopharmaceutical Tightens Governance Framework in Revised Articles; Confirms 9-Member Board and HK$517.95 Million Share Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=1153865036","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153865036?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:25","pubTimestamp":1781778348,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharmaceutical) has released its revised Articles of Association (effective June 2026), detailing updated corporate governance structures, capital...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644702139","title":"Xuanzhu Biopharmaceutical files director list with Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2644702139","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644702139?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:25","pubTimestamp":1781778311,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical filed an updated list of directors with the Hong Kong Stock Exchange on June 18, 2026.Xu Yanjun remains chairperson of the board, also serving as general manager.The board comprises executive, non-executive, employee representative, and independent non-executive directors; key committee chairs are held by independent directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDLbTRqvN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1191","BK1515","02575","00460","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644611702","title":"Xuanzhu Biopharma names Yue Xin employee representative director after election","url":"https://stock-news.laohu8.com/highlight/detail?id=2644611702","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644611702?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:21","pubTimestamp":1781778080,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical named Yue Xin as employee representative director, effective June 18, 2026.Yue replaces an executive director seat as the board shifts its composition.Li Jia Kui’s resignation as executive director takes effect immediately on Yue’s appointment.Yue served as a company supervisor from November 2021 to June 2026.She joined the group in 2019, rising from administrative assistant to head of administration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDLbVnXtt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1600","00460","BK1191","02575","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147854758","title":"Xuanzhu Bio Converts 357.25 Million Unlisted Shares to H Shares, Expanding Total Issued Capital to 517.95 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1147854758","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147854758?lang=en_us&edition=fundamental","pubTime":"2026-06-04 19:03","pubTimestamp":1780571015,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Bio) disclosed its Monthly Return for Equity Issuer for the period ended 31 May 2026, highlighting a substantial restructuring of its share structure...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173805012","title":"XUANZHUBIO-B Shares Surge as Three Key Products Advance to Commercial Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1173805012","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173805012?lang=en_us&edition=fundamental","pubTime":"2026-06-04 14:50","pubTimestamp":1780555828,"startTime":"0","endTime":"0","summary":"Shares of XUANZHUBIO-B (02575) rose more than 5% in trading. At the time of writing, the stock was up 5.17% to HK$17.29, with a turnover of HK$46.84 million. Key Drivers Behind the Move A recent...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK1191","02575","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123331571","title":"Xuanzhu Biopharma to Seek Shareholder Nod on 2025 Reports, Profit Distribution and Board Mandates at 18 June 2026 AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=1123331571","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123331571?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:04","pubTimestamp":1779872659,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharma) has issued the proxy form and agenda for its annual general meeting scheduled for 10:30 a.m. on Thursday, 18 June 2026 at the Jing Tai Lan...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638080355","title":"Xuanzhu Biopharmaceutical announces annual general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2638080355","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638080355?lang=en_us&edition=fundamental","pubTime":"2026-05-27 16:52","pubTimestamp":1779871976,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical will hold its 2025 annual general meeting in Beijing on June 18, 2026.Shareholders will vote on the 2025 annual report package, including the board report, supervisory committee report, audited consolidated financial statements.A profit distribution plan will be tabled, with the board not recommending a final dividend for 2025.Items include a directors’ remuneration plan, reappointment of Ernst & Young as 2026 auditor, estimated audit fee RMB 2 million.Special resolutions cover mandates to repurchase up to 10% of issued H shares, issue up to 20%, abolish the supervisory committee, amend the articles.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original conten","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL5RwMrH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1593","BK1515","BK1600","02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638518902","title":"Xuanzhu Biopharmaceutical seeks bylaw changes to scrap supervisory committee, shift oversight to audit committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2638518902","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638518902?lang=en_us&edition=fundamental","pubTime":"2026-05-26 17:46","pubTimestamp":1779788807,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical proposed bylaw amendments to abolish its supervisory committee, shifting oversight to an audit committee.Board structure would add an employee representative director as a non-executive, elected via an employee representative meeting.Executive director Li Jia Kui’s resignation would take effect upon that appointment, filling the vacancy created by his departure.Post-change board would comprise 2 executive directors, 4 non-executive directors, 3 independent non-executive directors.Shareholders will vote on the amendments at the June 18, 2026 AGM via special resolution.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL62ZvLc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1600","02575","BK1515","BK1593","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100532115","title":"Registration Open for \"Zhihui Financial 2026 Summer Roadshow Conference\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1100532115","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100532115?lang=en_us&edition=fundamental","pubTime":"2026-05-18 10:47","pubTimestamp":1779072449,"startTime":"0","endTime":"0","summary":"In the first half of 2026, the Hong Kong capital market is experiencing a long-awaited period of heightened activity. Since the second quarter, the Hong Kong market has been on a sustained recovery...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02670","BK1198","BK1129","00826","01021","HK0001040143.USD","00305","BK1207","BK1162","02142","LU1813983027.USD","BK1500","BK1144","BK1110","BK4585","06051","LU1719994722.HKD","02411","02675","BK1141","BK1578","02623","BK1190","02655","02685","00290","LU1251922891.USD","SG9999014674.SGD","LU0264606111.USD","BK1109","02729","BK1238","BK1147","02526","LU1023057109.AUD","00363","01907","BK1613","02228","BK1539","LU0572940350.SGD","LU1224709979.USD","BK1258","02650","01396","09696","LU1303224171.USD","LU1770034418.SGD","03858","00400","03317","BK1171","BK1155","BK4588","06636","01300","02706","LU0173614495.USD","BK1169","LU0359201612.USD","BK1161","BK1132","02565","BK1594","BK1163","BK1175","LU0345781412.USD","LU0345780950.USD","LU0469268626.HKD","BK1142","BK1229","LU0588546209.SGD","01333","02726","02652","LU0572939691.SGD","BK1592","LU1328277881.USD","SG9999001093.SGD","VXUS","02659","BK1541","BK1225","LU0630314457.HKD","LU0737861699.HKD","BK1240","BK1583","BK1249","06651","01384","BK1617","LU0359202008.SGD","BK1205","01378","BK1116","BK1117","BK1149","BK1100","BK1574","02575","LU0359201885.HKD","HK0001040168.HKD","LU2039709279.SGD","03881","06090","BK1506","LU0702159699.USD","LU0287142896.SGD","LU0314109678.HKD","06938","08299","LU0307460666.USD","BK1230","BK1191","02889","BK1183","00650","LU1166156734.SGD","06682"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175245965","title":"Xuanzhu Biopharma Converts 357.25 Million Unlisted Shares into H Shares, Lifting Issued Share Base by 68.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175245965","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175245965?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:02","pubTimestamp":1778583763,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharma) has completed the conversion of 357.25 million unlisted shares into the same number of H shares, according to its Next Day Disclosure Return...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112216216","title":"Xuanzhu Biopharmaceutical Completes H-Share Full Circulation, Converts 357.25 Million Unlisted Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1112216216","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112216216?lang=en_us&edition=fundamental","pubTime":"2026-05-12 17:03","pubTimestamp":1778576591,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. announced on 12 May 2026 that it has finalised its H-share full-circulation programme, converting 357.25 million unlisted domestic shares into H shares. The newly...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126727555","title":"XUANZHUBIO-B Completes Full Circulation of H Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1126727555","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126727555?lang=en_us&edition=fundamental","pubTime":"2026-05-12 16:34","pubTimestamp":1778574869,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) has announced that on May 12, 2026, a total of 357 million non-tradable shares have been converted. These converted H shares will commence trading on the Stock Exchange starting at 9:00 a.m. on May 13, 2026.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634296712","title":"Xuanzhu Biopharmaceutical converts 357,245,794 unlisted shares into H shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2634296712","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634296712?lang=en_us&edition=fundamental","pubTime":"2026-05-12 16:31","pubTimestamp":1778574709,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical completed conversion of 357,245,794 unlisted shares into H shares on May 12.Converted H shares start trading in Hong Kong at 9:00 a.m. on May 13.H-share count rises to 517,947,790 from 160,701,996; unlisted shares drop to zero.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL6srlSn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1600","BK1191","BK1515","00460","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633972317","title":"Here's Why We're Not Too Worried About Xuanzhu Biopharmaceutical's (HKG:2575) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2633972317","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633972317?lang=en_us&edition=fundamental","pubTime":"2026-05-06 07:15","pubTimestamp":1778022949,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2575/xuanzhu-biopharmaceutical-shares/news/heres-why-were-not-too-worried-about-xuanzhu-biopharmaceutic","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2575/xuanzhu-biopharmaceutical-shares/news/heres-why-were-not-too-worried-about-xuanzhu-biopharmaceutic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196960560","title":"XUANZHUBIO-B Accelerates Domestic Commercialization and Secures Major Overseas Licensing Deal, Broadening Growth Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=1196960560","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196960560?lang=en_us&edition=fundamental","pubTime":"2026-04-28 08:27","pubTimestamp":1777336035,"startTime":"0","endTime":"0","summary":"Revenue surged by over 70% year-on-year, signaling imminent commercialization breakthroughs for its three key drivers... In 2025, XUANZHUBIO-B successfully entered a phase of full-scale...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":85,"code":"91000000","status":"200"}]}}